CA2872856A1 - Methodes permettant d'empecher la formation de biofilms - Google Patents

Methodes permettant d'empecher la formation de biofilms Download PDF

Info

Publication number
CA2872856A1
CA2872856A1 CA2872856A CA2872856A CA2872856A1 CA 2872856 A1 CA2872856 A1 CA 2872856A1 CA 2872856 A CA2872856 A CA 2872856A CA 2872856 A CA2872856 A CA 2872856A CA 2872856 A1 CA2872856 A1 CA 2872856A1
Authority
CA
Canada
Prior art keywords
antibody
pnag
seq
set forth
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2872856A
Other languages
English (en)
Inventor
Jeremy Yethon
Astrid REY
Sylvie LEFORT
Laurent Fraisse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA2872856A1 publication Critical patent/CA2872856A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2872856A 2012-05-07 2013-05-06 Methodes permettant d'empecher la formation de biofilms Abandoned CA2872856A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261643650P 2012-05-07 2012-05-07
US61/643,650 2012-05-07
FRFR1352399 2013-03-18
PCT/US2013/039724 WO2013169657A1 (fr) 2012-05-07 2013-05-06 Méthodes permettant d'empêcher la formation de biofilms

Publications (1)

Publication Number Publication Date
CA2872856A1 true CA2872856A1 (fr) 2013-11-14

Family

ID=48464117

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2872856A Abandoned CA2872856A1 (fr) 2012-05-07 2013-05-06 Methodes permettant d'empecher la formation de biofilms

Country Status (8)

Country Link
EP (1) EP2847216A1 (fr)
CN (1) CN104662042A (fr)
AU (1) AU2013259786A1 (fr)
CA (1) CA2872856A1 (fr)
HK (1) HK1208475A1 (fr)
MX (1) MX2014013637A (fr)
SG (1) SG11201407209YA (fr)
WO (1) WO2013169657A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3162238A1 (fr) * 2019-11-22 2021-05-27 Alopexx, Inc. Procedes pour fournir une therapie continue contre des microbes contenant pnag

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (fr) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2262405A1 (fr) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1724282B1 (fr) 1997-05-21 2013-05-15 Merck Patent GmbH Procédé de production de protéines non-immunogènes
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
EP1006183A1 (fr) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
CA2342967A1 (fr) 1998-12-08 2000-06-15 Biovation Limited Modification de l'immunogenicite de proteines
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (fr) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRENANT UNE VARIANTE DE LA REGION Fc DE L'IgG1 HUMAIN
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP3502133A1 (fr) 2002-09-27 2019-06-26 Xencor, Inc. Variantes fc optimisées et leurs procédés de génération
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1587540B1 (fr) 2003-01-09 2021-09-15 MacroGenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
EP1664116A4 (fr) 2003-08-22 2009-06-03 Biogen Idec Inc Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
UA86605C2 (ru) 2004-01-12 2009-05-12 Аплайд Молекьюлер Иволюшн, Инк. Антитело, которое содержит вариант исходного человеческого fс-участка
WO2005092925A2 (fr) 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee

Also Published As

Publication number Publication date
AU2013259786A1 (en) 2014-11-20
HK1208475A1 (en) 2016-03-04
WO2013169657A1 (fr) 2013-11-14
EP2847216A1 (fr) 2015-03-18
SG11201407209YA (en) 2014-12-30
CN104662042A (zh) 2015-05-27
MX2014013637A (es) 2015-02-05

Similar Documents

Publication Publication Date Title
US11136398B2 (en) PDGF receptor beta binding polypeptides
US10465002B2 (en) Nucleic acids encoding antibodies to Kallidin and des-Arg10-Kallidin and host cells comprising the same
WO2009029132A2 (fr) PROTÉINES DE LIAISON À L'ANTIGÈNE CIBLANT L'ORF0657n DE S. AUREUS
US11814441B2 (en) Bi-specific antigen-binding polypeptides
KR102120620B1 (ko) 면역글로불린을 이용한 점막염의 치료
US20150086601A1 (en) Methods for preventing biofilm formation
CA2872856A1 (fr) Methodes permettant d'empecher la formation de biofilms
US20150210755A1 (en) Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection
Li et al. Antibodies to kallidin and des-Arg 9-kallidin

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180510